Navigation Links
Stiefel Launches Most-Prescribed BPO Wash Formulations Over-the-Counter
Date:2/4/2011

RESEARCH TRIANGLE PARK, N.C., Feb. 4, 2011 /PRNewswire/ -- Stiefel, a GSK company, today announced the launch of the most-prescribed BPO Acne Wash formulations for over-the-counter (OTC) use in the United States. The launch will occur in the technical exhibit at the American Academy of Dermatology annual meeting in New Orleans. Indicated for the treatment of acne, Stiefel will market two products OTC under the PanOxyl® Brand.  PanOxyl® Acne Creamy Wash will be available in 4% BPO and 8% BPO.  

PanOxyl® 4% and 8% BPO Acne Creamy Washes feature a patented delivery system including Dimethyl Isosorbide (DMI) that solubilizes BPO and greatly reduces particulate-based skin irritation and inflammation commonly experienced with conventional BPO formulations.  Both products are thick, creamy formulations which provide excellent efficacy and rapid reduction in acne lesions.  

"Stiefel's Creamy Wash formulations have been physician favorites for several years," said Shayne Sundholm, vice president, U.S. Non Prescription Dermatology, Stiefel.  "And we are excited to be able to offer them to a larger number of consumers through the retail market."  

A comprehensive marketing campaign directed toward dermatologists and pharmacists will communicate details of the new PanOxyl® 4% and 8% BPO Acne Creamy Washes.  Product will be available for shipment in May 2011.  

PanOxyl® Acne Management product line offers different formulations for the treatment and prevention of acne on the face, chest and back.  

www.panoxyl-skincare.com

About Stiefel, a GSK company  

Stiefel, a GSK company, is committed to advancing dermatology and skin science around the world in order to help people better achieve healthier skin.  Stiefel's dedication to innovation, along with its focus on pharmac
'/>"/>

SOURCE Stiefel, a GSK company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
2. Prasco and Stiefel Sign Distribution and Supply Agreement for Clobetasol Propionate Foam
3. RoundTable Healthcare Partners Names Charles W. Stiefel as Senior Advisor
4. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
5. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
6. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
7. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
8. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
9. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
10. Premier Micronutrient Launches Supplement for Hearing Health
11. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 Reportlinker.com announces that ... its catalogue: Acute Heart Failure Global ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute Heart Failure ... Summary GlobalData,s clinical trial report, "Acute Heart ... data on the Acute Heart Failure clinical trial ...
(Date:9/2/2014)... 2, 2014    - ... muestran agentes antitrombóticos no utilizados óptimamente para prevenir ... Las presentaciones de GARFIELD-AF en el ESC CONGRESS ... los resultados de pacientes en riesgo de sufrir ... Los datos de casi 12.500 pacientes ...
(Date:9/2/2014)... , -- GARFIELD-AF ... into treatment and outcomes of patients at risk ... Data from nearly 12,500 patients enrolled ... Fibrillation (GARFIELD-AF), an innovative, independent academic research initiative, ... fibrillation (AF) patients remain sub-optimal despite the transition ...
Breaking Medicine Technology:Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... Solutions Development Company (MSDC), a drug discovery and ... metabolic diseases, announced today that it has launched ... second drug candidate for the treatment of type ... placebo-controlled clinical trial will involve approximately 125 patients ...
... SAN and NYSE: SNY ) announced today ... Rights (CVRs) offered to Genzyme shareholders as part of ... by the U.S. Securities and Exchange Commission. ... Genzyme, sanofi-aventis has commenced an exchange offer to acquire ...
Cached Medicine Technology:Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 3
(Date:9/2/2014)... -- Complications are rare among breast cancer patients ... indicates. However, the researchers did find that ... higher risk for certain complications than a single ... breast cancer patients who had a single (64 ... and were followed for 30 days after surgery. ...
(Date:9/2/2014)... their own spread throughout the body by coaxing cells ... to a new report by Johns Hopkins scientists. , ... Communications , the researchers describe animal and cell-culture experiments ... by breast cancer cells. These molecules cause lymphatic endothelial ... produce proteins called CCL5 and VEGF. CCL5 attracts tumor ...
(Date:9/2/2014)... (PRWEB) September 03, 2014 Operators in ... to millions of people annually, arranging care and counsel ... and private enterprises are expected to derive $39.4 billion ... donations and private income. Over the five years through ... annualised rate of 6.6%, including growth of 4.1% in ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Melatonin supplements did not ... fractures, a new study found. Many older hospital ... due to disruption of their normal sleep-wake cycle. A ... that contributes to delirium, but there has been little ... This study included 378 patients, average age 84, ...
(Date:9/2/2014)... Steven Reinberg HealthDay Reporter ... the Ebola outbreak continues to overwhelm health-care workers in ... States and the United Nations called on Tuesday for ... of the often-fatal virus. Dr. Thomas Frieden, director ... said that without a greater global commitment in resources ...
Breaking Medicine News(10 mins):Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:More Global Help Needed to Fight Ebola Outbreak 2Health News:More Global Help Needed to Fight Ebola Outbreak 3
... screening program to detect peripheral arterial disease (PAD) on time ... For Life? this program can help detect the onset of ... of having an amputation by half. // ... affects every vascular bed in the body and it increases ...
... has the remarkable ability to discriminate between self and ... immune system, the human body would have lost its ... // ,The immune system produces certain substances ... cells, effectively labeling them as "bad" so that other ...
... Baptist Medical Center certain herbs and dietary supplements can ... other gastrointestinal problems.// ,The researcher Kemper, had ... were out there doing, and came up with a ... historically, 50 years ago, people used home remedies. Then ...
... unusual antibiotics that have the potential to be effective ... at the 230th national meeting of the American Chemical ... ,The new antibiotics are synthetic forms of cephalosporin, a ... kill bacteria by masquerading as components of the bacterial ...
... a research team led by the National Human Genome ... experimental anti-cancer drugs also shows promise in laboratory studies ... aging. // ,These drugs belong to a ... tested in people with myeloid leukemia, neurofibromatosis and other ...
... loss of interest in eating during old age is the ... a plan which will help older people eat nutritious food ... ,Doctors at the institute advise that High fibre in ... can help fight diabetes, heart disease and diverticulosis. Folic acid ...
Cached Medicine News:Health News:Diabetic Amputation May Reduce If Free Screenings Are There 2Health News:Fighting against disease as easy as eating eggs 2Health News:Atypical Antibiotics For Super Bugs 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: